Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Menin-MLL inhibitor

DRUG CLASS:

Menin-MLL inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	revumenib Sensitive: B - Late Trials revumenib Sensitive : B	revumenib Sensitive: B - Late Trials revumenib Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	DSP-5336 Sensitive: B - Late Trials DSP-5336 Sensitive : B	DSP-5336 Sensitive: B - Late Trials DSP-5336 Sensitive : B
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2	revumenib Sensitive: C2 – Inclusion Criteria revumenib Sensitive : C2
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2	ziftomenib Sensitive: C2 – Inclusion Criteria ziftomenib Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2	venetoclax + revumenib Sensitive: C2 – Inclusion Criteria venetoclax + revumenib Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	JNJ-6617 Sensitive: C2 – Inclusion Criteria JNJ-6617 Sensitive : C2	JNJ-6617 Sensitive: C2 – Inclusion Criteria JNJ-6617 Sensitive : C2